Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leuprorelin 3‑month depot in central precocious puberty
2022-002471-11Phase 4
- Sponsor
- Takeda
- Start
- Aug 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of leuprolide in central precocious puberty (CPP), sponsored by Takeda. Primary endpoint: Peak LH suppression following GnRH stimulation.
02
Drugs
leuprolide
03
Conditions
central precocious puberty (CPP)
Beyond the preview
Go deeper on 2022-002471-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002471-11.